ZTS

ZOETIS
D

ZTS

Arincen80/100B

ZOETIS financials

Yes. ZOETIS earned 2.49B USD of net income over the last twelve months, 26.1% of its revenue. It made a profit in 16 of its 17 fiscal years since 2009. Its last loss was in fiscal year 2009.

Revenue (TTM)
9.51B USD
Net income (TTM)
2.49B USD
Free cash flow (TTM)
2.28B USD
Cash and short-term investments
1.53B USD
Total debt
9.24B USD
Shareholders' equity
3.30B USD

Cash, debt and equity as of 30 Sept 2026.

ZOETIS earnings

Next earnings · Q4 FY2026
EPS estimate
1.22 USD
Revenue estimate
2.18B USD
Last quarter · Q3 FY2026
EPS1.75Beat +15.9%Revenue2.39BBeat +3.8%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q2 FY20281.96———2.51B———
Q1 FY20281.56——+4.49%2.28B——+1.48%
Q1 FY20271.49——-2.66%2.24B——-0.85%
Q4 FY20261.22——-17.57%2.18B——-8.79%
Q3 FY20261.511.75+15.89%+2.94%2.30B2.39B+3.79%-0.38%
Q2 FY20261.851.87+1.08%+6.25%2.50B2.47B-1.34%+0.33%
Q1 FY20261.601.53-4.38%+3.38%2.30B2.26B-1.71%+1.89%
Q4 FY20251.401.48+5.71%+5.71%2.36B2.39B+1.14%+3.02%
Q3 FY20251.621.70+4.94%+7.59%2.41B2.40B-0.41%+0.50%
Q2 FY20251.621.76+8.64%+12.82%2.41B2.46B+2.10%+4.19%

ZOETIS growth and profitability

Full income statement
Revenue (TTM)
9.51B USD
Net income (TTM)
2.49B USD
Gross margin
71.02%
Operating margin
36.26%
Net margin
26.15%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY20259.47B+2.28%2.67B+7.52%70.49%38.00%28.23%4.07B+5.09%
FY20249.26B+8.33%2.49B+6.06%69.10%36.65%26.86%3.87B+5.07%
FY20238.54B+5.74%2.34B+10.88%68.28%35.92%27.43%3.69B+9.74%
FY20228.08B+3.91%2.11B+3.78%67.77%36.24%26.16%3.36B+5.86%
FY20217.78B+16.49%2.04B+24.36%68.31%36.05%26.20%3.17B+18.09%

How ZOETIS makes its money

Revenue9.47B 100.0%
Cost of revenue2.79B 29.5%
Gross profit6.67B 70.5%
Research and development698.00M 7.4%
Selling and administration2.38B 25.1%
Operating income3.60B 38.0%
Tax687.00M 7.3%
Other expense237.00M 2.5%
Net income2.67B 28.2%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

ZOETIS revenue breakdown

By product

FY2025
Horses: 67.8%Cattle: 16.1%Swine: 5.0%Poultry: 4.7%Dogs and Cats: 3.3%Fish: 3.1%67.8%Horses16.1%Cattle5.0%Swine4.7%Poultry3.3%Dogs and Cats3.1%Fish
SegmentRevenueShare of revenueChange on the year
Horses6.28B67.8%+4.8%
Cattle1.49B16.1%-2.5%
Swine466.00M5.0%-9.7%
Poultry432.00M4.7%-18.0%
Dogs and Cats304.00M3.3%+6.7%
Fish286.00M3.1%+18.2%

By region

FY2025
United States: 54.5%International: 45.5%54.5%United States45.5%International
RegionRevenueShare of revenueChange on the year
United States5.10B54.5%+0.5%
International4.25B45.5%+3.7%

Operating and free cash flow

Full cash flow statement
Operating cash flow Free cash flow
Fiscal yearOperating cash flowFree cash flow
FY20252.90B2.28B
FY20242.95B2.30B
FY20232.35B1.62B
FY20221.91B1.33B
FY20212.21B1.74B
FY20202.13B1.67B
FY20191.80B1.34B
FY20181.79B1.45B
FY20171.35B1.12B
FY2016713.00M497.00M

ZOETIS financial health

Full balance sheet
Cash and short-term investments
1.53B USD
Total debt
9.24B USD
Net cash
-7.70B USD
Free cash flow (TTM)
2.28B USD
Current ratio
2.35
Debt to equity
2.80
Piotroski score
6 / 9
Altman Z-score
4.80

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20252.31B9.44B2.28B
FY20241.99B6.74B2.30B
FY20232.04B6.76B1.62B
FY20223.58B8.09B1.33B
FY20213.48B6.74B1.74B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity
Fiscal yearTotal assetsTotal liabilitiesShareholders' equity
FY202515.47B12.14B3.33B
FY202414.24B9.47B4.77B
FY202314.29B9.30B5.00B
FY202214.93B10.52B4.41B
FY202113.90B9.36B4.54B
FY202013.61B9.84B3.77B
FY201911.55B8.84B2.71B
FY201810.78B8.59B2.19B
FY20178.59B6.80B1.77B
FY20167.65B6.15B1.49B

ZOETIS valuation

Price to earnings ratio (TTM)
14.07
Forward P/E (FY2026)
13.13
Price to sales (TTM)
3.54
Price to book
10.19
EV / EBITDA (TTM)
10.79

Capital structure

Market capitalization
33.67B USD
+
Total debt
9.24B USD
−
Cash and short-term investments
1.53B USD
=
Enterprise value
41.37B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)12.32————
FY2027 (est.)13.1312.32———
FY2026 (est.)13.1313.13———
Now (TTM)14.0713.133.5410.1910.79
FY202520.8719.945.8916.7515.48
FY202429.7925.708.0015.5120.34
FY202338.8533.5410.6518.2225.98
FY202232.4927.098.5015.6021.81
FY202156.8849.9914.8925.4837.52

ZOETIS against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Viatris, Elanco Animal Health, Amneal Pharmaceuticals, and Lantheus Holdings, the US Drug Manufacturers - Specialty & Generic companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Below its median14.1
    11.459.3
  • Gross marginHighest in 5 years70.5%
    67.8%70.5%
    Against its peers: 1 of 5Peers' median 40.6%
  • Operating marginHighest in 5 years38.0%
    35.9%38.0%
    Against its peers: 1 of 5Peers' median 9.7%
  • Net marginHighest in 5 years28.2%
    26.2%28.2%
    Against its peers: 1 of 5Peers' median -1.3%
  • Return on equityHighest in 5 years80.2%
    44.8%80.2%
    Against its peers: 1 of 4Peers' median -3.5%
  • Free cash flow marginAbove its median24.1%
    16.4%24.8%
    Against its peers: 1 of 5Peers' median 11.2%
  • Revenue growthLowest in 5 years2.3%
    2.3%16.5%
    Against its peers: 3 of 5Peers' median 3.4%
  • EPS growthAt its median10.1%
    5.2%24.9%
    Against its peers: 1 of 3Peers' median -95.5%
  • Debt to EBITDAAbove its median2.32×
    1.74×2.41×
    Against its peers: 2 of 4Peers' median 4.53×
  • Current ratioAt its median3.03
    1.753.86
    Against its peers: 1 of 5Peers' median 2.17

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

ZOETIS dividends

Annual dividend
2.12 USD
Dividend yield (indicated)
2.56%
Payout ratio
35.99%
Years of dividend growth
13
Frequency
Quarterly
Next payment
0.53 USD
Last ex-dividend date
30 Oct 2026
Next payment date
1 Dec 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share2.001.731.501.301.000.800.660.500.420.38

ZOETIS ownership

Institutions
95.14%
Institutional holders
1,496 (-176)
Free float
99.79%

Who owns the shares

Institutions 95.1% Others 4.9%
As of 30 Jun 2026

Shares free to trade

Free float 405.46M shares ·99.8% Closely held 853.27K shares ·0.2%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q3 20260084.88K7.72K
Q2 20263030.94K15.25K
Q1 202602426.59K108.74K
Q4 2025003.50K0.00

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025443.44M443.84M-2.42%
FY2024454.20M454.85M-1.61%
FY2023461.17M462.27M-1.73%
FY2022468.89M470.39M-1.33%
FY2021474.35M476.72M-0.39%

Common questions about ZOETIS's financials

Source: Financial Modeling Prep